^
Association details:
| Biomarker: | IDH1 mutation |
|---|---|
| Cancer: | Chronic Myeloid Leukemia |
| Drug: | Venclexta (venetoclax) (Bcl2 inhibitor) + Tibsovo (ivosidenib) (IDH1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A phase Ib/II study of ivosidenib with venetoclax +/- azacitidine in IDH1-mutated myeloid malignancies
Published date:
04/27/2023
Excerpt:
The safety and efficacy of combining the IDH1 inhibitor ivosidenib (IVO) with the BCL2 inhibitor venetoclax (VEN; IVO+VEN) +/- azacitidine (AZA; IVO+VEN+AZA) was evaluated in four cohorts of patients with IDH1-mutated myeloid malignancies…Composite complete remission with IVO+VEN+AZA vs. IVO+VEN was 90% vs. 83%....No IDH isoform switching or second-site IDH1 mutations were observed, indicating combination therapy may overcome established resistance pathways to single-agent IVO.
Secondary therapy:
azacitidine
DOI:
10.1158/2643-3230.BCD-22-0205
